Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

In view of the high risk of recurrent disease in stage III and IV ovarian cancer following primary first-line chemotherapy, a variety of maintenance and consolidation treatment strategies have been developed. These have included: radiation, intravenous or intraperitoneal chemotherapy, targeted thera...

Descripción completa

Detalles Bibliográficos
Autor principal: Rose, Peter G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255234/
https://www.ncbi.nlm.nih.gov/pubmed/35800381
http://dx.doi.org/10.20517/cdr.2022.01

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255234/
https://www.ncbi.nlm.nih.gov/pubmed/35800381
http://dx.doi.org/10.20517/cdr.2022.01

Ejemplares similares